





Integral BioSystems

Science at the Interface of Biology and Chemistry



Newsletter, April 2024



Integral BioSystems, a contract research organization focused on drug delivery and development, announces the publication of a monthly newsletter. We will update our collaborators on company updates, including any new patent grants, trademark grants, new collaborations, addition of functionality and conference/trade show updates. We welcome your participation!

--Shikha Barman, Ph.D., Founder, President and CEO

--Dave Karasic, Esq., Founder, COO, IP Counsel

2024 Planned Events



Integral BioSystems to Exhibit at ARVO 2024

Bedford, MA – Mar 4, 2024. Integral BioSystems LLC, Boston area CRO specializing in pharmaceutical formulation development, will be in the spotlight as a participating exhibitor during the ARVO 2024 Annual Meeting of the Association for Research in Vision and Ophthalmology from May 4 to May 8, 2024, to be held at the Seattle Convention Center, Seattle, WA.

Integral BioSystems' technical experts will be available at Booth# 1717 to answer questions about the company's CRO capabilities.



Integral BioSystems' wholly owned subsidiary Symphony Therapeutics has been selected to deliver an Innovation Pitch at TechConnect World to be held in Washington, D.C., June 17-19, 2024

Bedford, MA--Mar 1, 2024. Symphony Therapeutics, LLC has been selected to pitch to investors at the TechConnect World Conference, Washington, D.C., June 17-19, 2024. Symphony CEO, Shikha Barman, Ph.D. plans to pitch an UV-protective ophthalmic product, based on the company's

Integral BioSystems specializes in drug delivery, formulation development, analytical development and tech transfer for a variety of routes: ophthalmic, injectables, topical, transdermal, intranasal, otic, pulmonary. Please visit us at <https://www.integralbiosystems.com>, or send us a note at info@integralbiosystems.com.

proprietary OcuHeal lipid nanoparticle platform. In addition, the company's proprietary sustained release and dissolvable ophthalmic inserts, the NanoM Wafer platform will also be presented at the Symphony/Integral booth at TechConnect. If interested to know more, please email at bizdev@symphonytx.com. Symphony Therapeutics was founded in July 2022, as a wholly-owned subsidiary of Integral BioSystems.



Integral BioSystems, LLC, 23 Crosby Drive, Suite 100A, Bedford, MA 01730 | 781-275-8059 | info@integralbiosystems.com

Integral BioSystems, LLC | 23 Crosby Drive, Suite 100A, Bedford, MA 01730

[Unsubscribe samh@integralbiosystems.com](mailto:samh@integralbiosystems.com)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by bybd@integralbiosystems.ccsend.com powered by



Try email marketing for free today!